secwatch / observer
8-K filed May 5, 2026, 7:59 PM ET ticker PHGE CIK 0001739174
other material confidence high sentiment neutral materiality 0.90

BiomX exits phage therapy, pivots to defense/security via DFSL and Zorronet acquisitions

BiomX Inc.

item 8.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001213900-26-052213
form_type
8-K
ticker
PHGE
cik
0001739174
company_name
BiomX Inc.
filed_at
2026-05-05T23:59:59+00:00
discovered_at
2026-05-14T18:02:32.832896+00:00
generated_at
2026-05-14T23:28:53.994772+00:00
sec_items
["8.01"]
event_type
other_material
sentiment
neutral
materiality_score
0.9
calibrated_materiality_score
0.9
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001213900-26-052213
json_url
https://secwatch.observer/filing/0001213900-26-052213.json
markdown_url
https://secwatch.observer/filing/0001213900-26-052213.md
text_url
https://secwatch.observer/filing/0001213900-26-052213.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1739174/000121390026052213/0001213900-26-052213-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1739174/000121390026052213/ea0289209-8k_biomx.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Comparable filings

CWBHF

Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment

Charlotte's Web Holdings, Inc. June 1, 2026, 5:13 PM ET other_material Items 5.02, 5.07, 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

FULC

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc. June 1, 2026, 4:05 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

CORNER GROWTH ACQUISITION CORP. 2

Corner Growth Acquisition Corp. 2 to liquidate and dissolve after failing to complete business combination

CORNER GROWTH ACQUISITION CORP. 2 June 1, 2026, 4:00 PM ET other_material Items 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

Corner Growth Acquisition Corp.

Corner Growth Acquisition Corp. to liquidate; will redeem public shares

Corner Growth Acquisition Corp. June 1, 2026, 4:00 PM ET other_material Items 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

GPRO

GoPro refiles financials with going-concern warning; potential defaults on debt

GoPro, Inc. June 1, 2026, 9:12 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

STSS

Sharps Technology rebrands as SkyAI, pivots to AI finance platform for Global South

Sharps Technology Inc. June 1, 2026, 8:15 AM ET other_material Items 5.03, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR
accession 0001213900-26-052213
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.